Log In
Print this Print this

Captisol-enabled budesonide/azelastine nasal spray (CDX-313)

Also known as: budesonide/azelastine

  Manage Alerts
Collapse Summary General Information
Company Ligand Pharmaceuticals Inc.
DescriptionBudesonide and azelastin combined in solution by a chemically modified sulfobutylether beta-cyclodextrin
Molecular Target Corticoid receptors
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationRhinitis
Indication DetailsTreat seasonal allergic rhinitis (SAR)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today